Last reviewed · How we verify
desvenlafaxine SR
Desvenlafaxine SR is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.
Desvenlafaxine SR is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | desvenlafaxine SR |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter, Norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Depression, Anxiety |
| Phase | Phase 3 |
Mechanism of action
By blocking the reuptake of serotonin and norepinephrine, desvenlafaxine SR increases the amount of these neurotransmitters available for synaptic transmission, which can help improve mood and reduce symptoms of depression and anxiety.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Insomnia
Key clinical trials
- Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women (PHASE3)
- Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder (PHASE2)
- A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD (PHASE3)
- Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD) (PHASE3)
- A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD (PHASE3)
- A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD (PHASE3)
- A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- desvenlafaxine SR CI brief — competitive landscape report
- desvenlafaxine SR updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI